Posted by Michael Wonder on 07 Jan 2025
EMA commences review of donidalorsen in hereditary angioedema
6 January 2025 - Otsuka announces that the EMA has accepted for review the marketing authorisation application for the hereditary angioedema drug candidate donidalorsen (ISIS 721744) for routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older.
The drug was discovered and developed by Ionis Pharmaceuticals as a treatment for hereditary angioedema attacks.
